Disclosure of relevant interests
Initial Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(1) and 298(1), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
The a2 Milk Company Limited (ATM)
Date this disclosure made:
24-May-22
Date on which issuer listed or appointment made:
17-May-22
Director or senior manager giving disclosure
Full name:
Mark Sherwin
Name of listed issuer:
The a2 Milk Company Limited
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
Interim Chief Financial Officer
Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product:
(1) Unlisted performance rights
(Performance Rights) representing
an entitlement to acquire fully paid
ordinary shares in ATM (Ordinary
Shares).
(2) Ordinary Shares.
Number held in class:
(1) 9,927 Performance Rights due to
vest in August 2022 provided certain
performance conditions are met.
(2) 31,905 Performance Rights due
to vest on a date to be determined
by the Board following the release of
ATM’s full year audited results for
FY2023 provided certain
performance conditions are met.
(3) 32,076 Performance Rights due
to vest on a date to be determined
by the Board following the release of
ATM’s full year audited results for
FY2024 provided certain
performance conditions are met.
(4) 16,800 Ordinary Shares.
Nature of relevant interest:
Legal and beneficial owner
Current registered holder:
Mark Sherwin
Summary of specified derivatives relevant interest (if applicable)
Type of derivative:
N/A
Class of underlying financial products:
Details of derivative
N/A
The notional value of the derivative (if any) or the notional amount of underlying
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative(if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:24/05/2022
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- AIA — Auckland International Airport Limited: AIA – Initial Disclosure Notice2022-06-09
“1763045 Initial Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(1) and 298(1), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: Auckland Intern…”
- AIA — Auckland International Airport Limited: AIA – NZX Disclosure Notices – DEP2022-03-10
“1989961 6 March 2020 Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: Auc…”
- AFT — AFT Pharmaceuticals Limited: Disclosure of Directors and Senior Managers Relevant Intere2022-06-20
“Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: AFT Pharmaceuticals Limited (AFT) Date this disclosure made: 20-Jun-22 Date of las…”